NICE backs routine use of Incyte’s leukaemia drug
Draft guidelines published by the National Institute for Health and Care Excellence back the routine use of Incyte’s Iclusig on the NHS to treat some patients with chronic myeloid leukaemia and acute lymphoblastic leukaemia.
Read More
